KAMADA » MEDIA » NEWS

NEWS


Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Press Release / Jul. 20, 2017

Kamada announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) for review a proposed pivotal Phase 3 protocol for its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy (Inhaled AAT) for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).  

Kamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Press Release / Jun. 27, 2017

Kamada announced that the Company has withdrawn the Marketing Authorization Application (MAA) for its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) with the European Medicines Agency (EMA).

Kamada Receives Additional Milestone Payment Under GLASSIA® Exclusive Supply and Distribution Agreement with Shire

Press Release / Jun. 12, 2017

Kamada announced the receipt of an undisclosed additional milestone payment under the supply and distribution agreement with Shire for GLASSIA®, Kamada’s intravenous (IV) alpha-1 antitrypsin (AAT).

Kamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director

Press Release / Jun. 5, 2017

Kamada announced today the appointment of Michal Stein, M.D., as Vice President and Medical Director for Immunology.

Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference

Press Release / May. 24, 2017

Kamada announced that a poster comprising updated data from the Company’s U.S. Phase 2 clinical trial of its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) was presented by Professor Mark Brantly, M.D., Vice Chair of Research, Department of Medicine, Chief Division of Pulmonary, Critical Care and Sleep Medicine, Professor of Medicine, Molecular Genetics and Microbiology at the University of Florida College of Medicine and Alpha One Foundation Research Professor, at the 2017 American Thoracic Society (ATS) International Conference, being held May 19-24 in Washington, D.C. 

Kamada Reports 2017 First Quarter Financial Results

Press Release / May. 17, 2017

Reaffirms revenue guidance of $100 million for 2017
Proprietary Products segment for 2017 projected at $76-$78 million, up at least 36% compared to
2016.

Kamada to Host R&D Day Focused on Graft versus Host Disease (GvHD)

Press Release / Mar. 3, 2017

The company will host a Research and Development Day to highlight Graft versus Host Disease (GvHD) in New York City on March 3 from 12:00pm to 1:30pm Eastern Time.

Kamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation

Press Release / Feb. 21, 2017

The conpany announced today a collaboration with Massachusetts General Hospital (MGH) to conduct a proof of concept study evaluating the potential benefit of the Company’s Liquid Alpha-1 Antitrypsin (AAT) on liver preservation.

Kamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors

Press Release / Feb. 8, 2017

Kamada announced today the appointment of Gwen A. Melincoff to the Company’s Board of Directors.

Kamada Reports Financial Results for the Fourth Quarter and Full-Year 2016

Press Release / Feb. 6, 2017

Total revenues for 2016 were $77.5 million, an 11% increase over 2015. Full year 2016 Proprietary Product revenues up over 30%. Re-affirms revenue guidance of $100 million for 2017. Conference Call Today (Feb. 6) at 8:30am Eastern Time.

out of 107 items.